Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b dose-finding study of sisunatovir in pediatric RSV lower respiratory tract infection
jRCT2031230445Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Sisunatovir with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs), Incidence of adverse events (AEs) and serious adverse events (SAEs) leading to discontinuations and 3 more. Started Apr 2024; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031230445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230445.